Last reviewed: May 21, 2026

Last updated: May 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 (glucagon-like peptide-1) is produced primarily in intestinal L-cells located in the lower small intestine and colon, with smaller amounts secreted by pancreatic alpha cells. This hormone plays a central role in regulating blood glucose, slowing gastric emptying, and signaling satiety to the brain—making it a key driver of metabolic health.

For patients considering GLP-1-based therapy, understanding where and how this hormone works provides essential context for treatment decisions. Individual response to GLP-1 interventions varies significantly, and emerging evidence suggests genetic and biomarker factors may help explain why some patients experience robust benefits while others show more modest responses.

Start your GLP-1 program with PlexusDx

One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.

Start your intake →

Intestinal L-Cells: The Primary Source of GLP-1 Secretion

GLP-1 is synthesized and secreted by specialized enteroendocrine cells called L-cells, which are scattered throughout the intestinal epithelium but concentrated in the ileum and colon. These cells detect nutrient intake—particularly glucose and amino acids—and respond by releasing GLP-1 into the bloodstream within minutes of eating.

The amount of GLP-1 secreted varies between individuals based on diet composition, gut microbiota, intestinal health, and genetic factors. Patients with lower baseline GLP-1 secretion may benefit from GLP-1 therapy, while those with robust endogenous production may approach treatment differently. Understanding this variability is essential for personalized care.

How GLP-1 Affects Metabolism, Blood Sugar, and Appetite

GLP-1 exerts its metabolic effects through multiple mechanisms: it stimulates insulin secretion in response to meals, inhibits glucagon release when blood sugar is adequate, slows gastric emptying to extend nutrient absorption, and activates GLP-1 receptors in the hypothalamus to promote satiety signals.

These coordinated actions create a cascade of metabolic changes. By slowing digestion and enhancing insulin response, GLP-1 helps stabilize postprandial glucose spikes. Through central nervous system signaling, it reduces appetite and food intake. Combined, these effects support weight loss and improved glycemic control, though individual magnitude of response varies.

GLP-1 Action Target Tissue/Pathway Primary Health Effect
Insulin stimulation Pancreatic beta cells Lowers postprandial blood glucose
Glucagon inhibition Pancreatic alpha cells Reduces hepatic glucose output
Gastric emptying slowing Stomach smooth muscle Extends nutrient absorption window
Satiety signaling Hypothalamic appetite centers Reduces food intake and hunger
GLP-1R activation Cardiovascular and renal tissues May support cardiovascular and kidney health

Individual Variation in GLP-1 Response: The Genetic and Biomarker Story

Not all patients respond identically to GLP-1 therapy. Research suggests genetic variation in GLP-1 receptor expression, glucose metabolism, and appetite regulation genes influences individual treatment outcomes. Variants in GLP1R, GIPR, FTO, and MC4R genes may predispose patients toward greater or lesser responsiveness to GLP-1-based interventions.

Biomarkers including baseline fasting insulin, C-peptide levels, HbA1c, inflammatory markers (CRP, TNF-alpha), and adiposity distribution provide additional context. Patients with insulin resistance, elevated inflammatory markers, or genetic predispositions affecting peptide pathways may benefit from early, more tailored treatment conversations with their provider to optimize outcomes.

GLP-1 Therapy Options and Clinical Considerations for Your Healthcare Provider

GLP-1-based treatment comes in multiple formulations: branded injectables (Ozempic, Mounjaro, Zepbound), branded oral tablets, and compounded formulations from licensed 503A pharmacies. Compounded options provide cost flexibility and dosing customization while maintaining the same active pharmaceutical ingredients as branded medications, offering an alternative pathway for patients and providers.

Before starting any GLP-1 therapy, patients should work with a qualified healthcare provider to confirm medical eligibility, assess baseline kidney and pancreatic function, discuss potential side effects, and establish realistic expectations. Genetic testing and biomarker review can support more informed personalized discussions—though genetic predispositions indicate risk tendency, not certainty of individual medication response.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 and appetite-regulation pathways (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help provide context about your individual predisposition to GLP-1 sensitivity and metabolic responses. This information, interpreted with your healthcare provider, can support more informed treatment conversations.

The genetic test reveals predispositions in peptide pathways—not exact medication response predictions. A patient with a genetic variant associated with higher GLP-1 sensitivity may experience benefits at lower doses, while those with lower predicted sensitivity might benefit from more tailored dosing strategies. These insights work alongside clinical biomarkers (insulin levels, inflammation markers, kidney function) to build a more complete picture.

Understanding your GLP-1 pathway genetics and current metabolic biomarkers can help you and your provider design a more personalized treatment approach. Whether you choose compounded semaglutide, tirzepatide, or other GLP-1 therapies available through PlexusDx, combining genetic context with clinical evaluation supports more confident treatment decisions and realistic outcome expectations.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which cells in the body actually make GLP-1?

The article says GLP-1 is produced primarily by intestinal L-cells, specialized enteroendocrine cells scattered through the intestinal epithelium but concentrated in the ileum and colon. Smaller amounts come from pancreatic alpha cells. It adds that L-cells detect nutrients, particularly glucose and amino acids, and release GLP-1 into the bloodstream within minutes of eating.

What makes one person's natural GLP-1 output different from another's?

The post says the amount secreted varies between individuals based on diet composition, gut microbiota, and intestinal health. It notes that people with lower baseline GLP-1 secretion may benefit from GLP-1 therapy, while those with robust natural production may approach treatment differently. The article treats that variability as a reason for individualized care rather than a fixed rule.

Besides raising insulin, what else does GLP-1 do to blood sugar?

The article's table describes a second lever: GLP-1 inhibits glucagon release from pancreatic alpha cells when blood sugar is adequate, which reduces hepatic glucose output. Alongside that, slowing gastric emptying extends the nutrient absorption window and blunts post-meal glucose spikes. The post presents these as coordinated actions rather than a single mechanism.

Does GLP-1 act anywhere outside the gut and pancreas?

Yes, according to the article's table. It lists GLP-1 receptor activation in cardiovascular and renal tissues, with a stated effect of potentially supporting heart and kidney health. The post also describes receptors in hypothalamic appetite centers that drive satiety signaling and reduce food intake, which is why it frames GLP-1 as a multi-system hormone.

What does the post say should be confirmed with a provider before starting GLP-1 therapy?

It says patients should work with a qualified provider to confirm medical eligibility, assess baseline kidney and pancreatic function, discuss potential side effects, and establish realistic expectations. The article positions that evaluation as the step that comes before any decision about formulation, and it is clear that no informational content replaces that conversation.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves